Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Non-Current Assets (2023 - 2025)

Immunome (IMNM) has disclosed Non-Current Assets for 3 consecutive years, with $22.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non-Current Assets rose 18.56% year-over-year to $22.4 million, compared with a TTM value of $80.3 million through Dec 2025, up 60.19%, and an annual FY2025 reading of $22.4 million, up 18.56% over the prior year.
  • Non-Current Assets was $22.4 million for Q4 2025 at Immunome, up from $19.5 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $22.4 million in Q4 2025 and bottomed at $1.6 million in Q1 2023.
  • Average Non-Current Assets over 3 years is $11.6 million, with a median of $12.4 million recorded in 2024.
  • The sharpest move saw Non-Current Assets skyrocketed 636.0% in 2024, then increased 18.56% in 2025.
  • Year by year, Non-Current Assets stood at $3.8 million in 2023, then surged by 392.62% to $18.9 million in 2024, then rose by 18.56% to $22.4 million in 2025.
  • Business Quant data shows Non-Current Assets for IMNM at $22.4 million in Q4 2025, $19.5 million in Q3 2025, and $18.9 million in Q2 2025.